Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cheelcare Inc. ( (TSE:CHER) ).
Cheelcare reported record third-quarter 2026 revenue, driven by growing adoption of its Companion power-assist mobility device and expansion of its global dealer network, even as the company remained loss-making due to ongoing investments in manufacturing scale-up and regulatory readiness. Gross margin improved sharply as revenues rose 16% year over year, while a subsequent $1 million promissory note bolstered working capital amid continued production ramp-up.
A key milestone was U.S. Medicare and Medicaid reimbursement eligibility for the Companion device following PDAC and HCPCS recognition, a development expected to accelerate U.S. dealer adoption and strengthen Cheelcare’s market position. The company also advanced regulatory and reimbursement pathways for its Curio product and appointed experienced growth-stage finance executive Natasha Tsai as chief financial officer, signaling a shift from foundational buildout toward scaling operations.
More about Cheelcare Inc.
Cheelcare Inc. is a Canadian medical mobility technology company focused on advanced power-assist and wheelchair mobility solutions for users in North America and globally. Its flagship Companion power-assist device is sold through more than 500 dealer locations, including the top three dealer networks in North America, with the company operating a 16,000-square-foot manufacturing facility in Ontario.
Average Trading Volume: 32,921
Technical Sentiment Signal: Buy
See more data about CHER stock on TipRanks’ Stock Analysis page.